Obermatt

Extendicare

TOR:EXE · CA30224T8639
Health Care Providers & ServicesMedium

360

93
EV / EBIT81
Price / Owner Earnings24
Owner Earnings Yield57
Dividend Yield95
Price/Sales93
EV / Gross Profit24
Price/Book13
Return on Capital97
Cash Return on Capital98
Return on Equity98
EBIT Margin39
Gross Profitability59
Cash Conversion20
Accruals3
Owner Earnings Margin63
Sales growth85
Profit Growth79
Long-Term EPS Growth27
Owner Earnings Growth80
Reinvestment67
Price momentum98
Debt load25
Refinancing19
Debt Payback80
Liquidity89
Analyst ratings39
Opinion Changes90
Price Target Upside33
Market mood15
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Extendicare generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryCanada
IndustryHealth Care Providers & Services
SizeMedium
TypePublic Company
ExchangeTSX
Founded1968
Employees2,724
ISINCA30224T8639
Last UpdateApr 2, 2026
Index & Theme
Assisted LivingHealth Care

Description

Extendicare Inc., through its subsidiaries, provides care and services for seniors across Canada, operating under the Extendicare, Esprit Lifestyle, ParaMed, Extendicare Assist and SGP Partner Network brands. The company is also a private-sector pro…

Analysis

Middle-of-the-road

Extendicare Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is expensive. You pay 31.1× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is solid and the balance sheet is sturdy. The company scores 18/20 on our value-creation score: strong value creator.

What to watch: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
89
2023202420252026

All-time high

89

Jun 2026

All-time low

1

Jan 2024

Average rank

42

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
93
62
74
81
Price/Earnings
10
82
24
23
Price/Book
13
5
5
17
Dividend Yield
95
98
100
100
Value (overall)
74
76
67
68

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Extendicare with its peers
Cigna
NYQ:CI
59
CountryUSA
IndustryHealth Care Providers & Services
SizeXX-Large
Full Stock Analysis →
Day One Biopharmaceuticals
NSQ:DAWN
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Soleno Therapeutics
NAQ:SLNO
67
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Certara
NSQ:CERT
45
CountryUSA
IndustryHealth Care Technology
SizeMedium
Full Stock Analysis →
Recursion Pharmaceuticals
NSQ:RXRX
20
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
BridgeBio Oncology Therapeutics
NMQ:BBOT
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →